THE INDICATORS ASSOCIATED WITH RESPONSE TO CHEMOTHERAPY

For patients with advanced non-small cell lung cancer, the current standard treatment is a pair
In general, platinum-based chemotherapy, including configuration Drugs and gemcitabine (84). Complex compounds of platinum metals is And DNA molecules that form adducts with DNA, preventing the interface between Replication and transcription. Depending on the repair of these adducts and cross links The excision repair cross-complement the group 1 (ERCC1) (85). In non-small cell lung cancer The high levels of ERCC1 mRNA expression was associated with improved survival from surgery resected tumors (86, 87), and low levels of mRNA associated with greater overall Treatment with platinum-based survival of patients with advanced tumors. (88, The entire resected NSCLC and ERCC1-negative tumors to 89) patients protein expression by immunohistochemistry, which will help them benefit cisplatin-based chemotherapy, ERCC1-positive tumors have a patient, while No. (90). It can reduce damage to DNA repair mechanisms have been proposed The accumulation of genetic abnormalities are thought to contribute to tumor Malignant potential, so that the risk of recurrence after definitive therapy. In contrast, a low expression of ERCC1 reflects a defective DNA repair mechanism They respond well to chemotherapy based and severally liable for The survival of patients. Several studies of ribonucleotide reductase M1 polypeptide have shown (RRM1) Thus, an important determinant of cellular molecular target of gemcitabine and Treatment (87). RRM1 is located in Section chromosome 11p15.5
Frequently deleted in NSCLC (91) with the region. Low levels of gene expression NSCLC (92) is associated with poor survival. RRM1 introduced Nucleoside analog gemcitabine important cellular determinant of the effectiveness of (2 ¢, 2 ¢ difluorodeoxycytidine) (93). For a high level of surgical resection of NSCLC The survival of RRM1 protein expression by immunofluorescence (87) and care. Furthermore, RRM1 mRNA appears to provide increased levels Advanced NSCLC (93, 94) lack of efficacy in patients with gemcitabine.